TickerStat.comEloxx Pharmaceuticals annual net income
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2015
2016
2016
2017
2017
2018
2019
2020
2021
2022
2023
2024
2025
Eloxx Pharmaceuticals Net Income Growth & History (ELOX)
Eloxx Pharmaceuticals's net income was −$6.0M for fiscal 2025.
View full Eloxx Pharmaceuticals company overviewEloxx Pharmaceuticals annual net income history
| Fiscal year | Period ended | Net income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$6.0M | −$2.9M | — |
| 2024 | 2024-12-31 | −$3.1M | $13.9M | — |
| 2023 | 2023-12-31 | −$17.1M | $19.0M | — |
| 2022 | 2022-12-31 | −$36.1M | $30.7M | — |
| 2021 | 2021-12-31 | −$66.7M | −$32.1M | — |
| 2020 | 2020-12-31 | −$34.6M | $16.3M | — |
| 2019 | 2019-12-31 | −$50.9M | −$3.7M | — |
| 2018 | 2018-12-31 | −$47.2M | −$26.0M | — |
| 2017 · Dec 31 | 2017-12-31 | −$21.2M | −$11.4M | — |
| 2017 · Jun 30 | 2017-06-30 | −$5.8M | $2.5M | — |
| 2016 · Dec 31 | 2016-12-31 | −$9.8M | −$3.4M | — |
| 2016 · Jun 30 | 2016-06-30 | −$8.3M | $9.8M | — |
| 2015 · Dec 31 | 2015-12-31 | −$6.4M | — | — |
| 2015 · Jun 30 | 2015-06-30 | −$18.1M | −$8.8M | — |
| 2014 | 2014-06-30 | −$9.2M | −$3.1M | — |
| 2013 | 2013-06-30 | −$6.1M | −$1.1M | — |
| 2012 | 2012-06-30 | −$5.1M | $2.2M | — |
| 2011 | 2011-06-30 | −$7.3M | $6.1M | — |
| 2010 | 2010-06-30 | −$13.4M | −$7.7M | — |
| 2009 | 2009-06-30 | −$5.7M | −$1.1M | — |
| 2008 | 2008-06-30 | −$4.6M | −$1.3M | — |
| 2007 | 2007-06-30 | −$3.3M | $63,188 | — |
| 2006 | 2006-06-30 | −$3.3M | −$335,967 | — |
| 2005 | 2005-06-30 | −$3.0M | $748,033 | — |
| 2004 | 2004-06-30 | −$3.7M | −$948,947 | — |
| 2003 | 2003-06-30 | −$2.8M | $243,705 | — |
| 2002 | 2002-06-30 | −$3.0M | −$987,819 | — |
| 2001 | 2001-06-30 | −$2.0M | $1.3M | — |
| 2000 | 2000-06-30 | −$3.3M | −$2.2M | — |
| 1999 | 1999-06-30 | −$1.2M | — | — |
Eloxx Pharmaceuticals quarterly net income
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q4.15
Q1.16
Q4.16
Q1.17
Q4.16
Q1.17
Q4.17
Q1.18
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.25
Q2.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$4.5M | −$2.6M | — |
| Q1 2026 | 2026-03-31 | −$3.8M | −$2.0M | — |
| Q2 2025 | 2025-06-30 | −$1.9M | — | — |
| Q1 2025 | 2025-03-31 | −$1.7M | — | — |
| Q4 2023 | 2023-12-31 | −$2.9M | $3.4M | — |
| Q3 2023 | 2023-09-30 | −$3.6M | $3.9M | — |
| Q2 2023 | 2023-06-30 | −$4.3M | $6.3M | — |
| Q1 2023 | 2023-03-31 | −$6.2M | $5.4M | — |
| Q4 2022 | 2022-12-31 | −$6.3M | $5.8M | — |
| Q3 2022 | 2022-09-30 | −$7.5M | $2.4M | — |
| Q2 2022 | 2022-06-30 | −$10.6M | $25.4M | — |
| Q1 2022 | 2022-03-31 | −$11.6M | −$2.9M | — |
| Q4 2021 | 2021-12-31 | −$12.1M | −$6.0M | — |
| Q3 2021 | 2021-09-30 | −$9.9M | −$3.3M | — |
| Q2 2021 | 2021-06-30 | −$36.1M | −$28.2M | — |
| Q1 2021 | 2021-03-31 | −$8.7M | $5.3M | — |
| Q4 2020 | 2020-12-31 | −$6.1M | $5.5M | — |
| Q3 2020 | 2020-09-30 | −$6.6M | $6.3M | — |
| Q2 2020 | 2020-06-30 | −$7.9M | $6.6M | — |
| Q1 2020 | 2020-03-31 | −$13.9M | −$2.0M | — |
| Q4 2019 | 2019-12-31 | −$11.6M | $2.4M | — |
| Q3 2019 | 2019-09-30 | −$12.9M | −$1.7M | — |
| Q2 2019 | 2019-06-30 | −$14.4M | −$1.0M | — |
| Q1 2019 | 2019-03-31 | −$11.9M | −$3.3M | — |
| Q4 2018 | 2018-12-31 | −$14.0M | −$3.4M | — |
| Q3 2018 | 2018-09-30 | −$11.2M | −$7.1M | — |
| Q2 2018 | 2018-06-30 | −$13.4M | −$9.5M | — |
| Q1 2018 · Mar 31 | 2018-03-31 | −$8.6M | −$5.9M | — |
| Q4 2017 | 2017-12-31 | −$10.6M | −$9.8M | — |
| Q1 2018 · Sep 30 | 2017-09-30 | −$4.0M | −$3.1M | — |
| Q4 2017 | 2017-06-30 | −$3.9M | −$2.7M | — |
| Q1 2017 · Mar 31 | 2017-03-31 | −$2.7M | $401,113 | — |
| Q4 2016 | 2016-12-31 | −$789,831 | $3.1M | — |
| Q1 2017 · Sep 30 | 2016-09-30 | −$933,577 | −$752,834 | — |
| Q4 2016 | 2016-06-30 | −$1.2M | −$245,877 | — |
| Q1 2016 · Mar 31 | 2016-03-31 | −$3.1M | −$1.9M | — |
| Q4 2015 | 2015-12-31 | −$3.9M | $6.9M | — |
| Q1 2016 · Sep 30 | 2015-09-30 | −$180,743 | $5.0M | — |
| Q4 2015 | 2015-06-30 | −$906,776 | $2.8M | — |
| Q3 2015 | 2015-03-31 | −$1.2M | $919,679 | — |
| Q2 2015 | 2014-12-31 | −$10.7M | −$9.1M | — |
| Q1 2015 | 2014-09-30 | −$5.2M | −$3.4M | — |
| Q4 2014 | 2014-06-30 | −$3.7M | −$1.7M | — |
| Q3 2014 | 2014-03-31 | −$2.1M | −$1.3M | — |
| Q2 2014 | 2013-12-31 | −$1.6M | −$349,753 | — |
| Q1 2014 | 2013-09-30 | −$1.8M | $301,121 | — |
| Q4 2013 | 2013-06-30 | −$1.9M | −$491,700 | — |
| Q3 2013 | 2013-03-31 | −$836,583 | $224,076 | — |
| Q2 2013 | 2012-12-31 | −$1.3M | $257,686 | — |
| Q1 2013 | 2012-09-30 | −$2.1M | −$1.0M | — |
| Q4 2012 | 2012-06-30 | −$1.4M | $1.3M | — |
| Q3 2012 | 2012-03-31 | −$1.1M | $344,449 | — |
| Q2 2012 | 2011-12-31 | −$1.5M | −$391,008 | — |
| Q1 2012 | 2011-09-30 | −$1.0M | $976,493 | — |
| Q4 2011 | 2011-06-30 | −$2.7M | — | — |
| Q3 2011 | 2011-03-31 | −$1.4M | — | — |
| Q2 2011 | 2010-12-31 | −$1.1M | — | — |
| Q1 2011 | 2010-09-30 | −$2.0M | — | — |
Eloxx Pharmaceuticals net income trends
Over the last five fiscal years, Eloxx Pharmaceuticals's net income increased from −$34.6M to −$6.0M, a change of $28.6M. The latest reported quarter, Q2 2026, shows −$4.5M.
About the metric
What net income means
Net income is a company’s bottom-line profit or loss after operating costs, interest, taxes, and other reported income and expenses. It shows how much of a company’s revenue ultimately remained as earnings, or how large its loss was, during a fiscal period.
Calculation and source
SEC-reported net income
TickerStat standardizes consolidated net income or profit and loss reported in company SEC filings for aligned fiscal periods. It is not adjusted earnings, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Eloxx Pharmaceuticals source filings ↗Community posts
Eloxx doses first patients in mid-stage Alport syndrome trial
Eloxx Pharmaceuticals ($ELOX) dosed the first two patients in its Phase 2b EXACT study of exaluren for Alport syndrome caused by nonsense mutations. The trial plans to enroll 24 patients with relevant mutations in the COL4A3, COL4A4 or COL4 ...